Arcutis Biotherapeutics, Inc. (ARQT) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Arcutis Biotherapeutics, Inc.

Arbutus Biopharma Corp.

SIGA Technologies, Inc.

ARS Pharmaceuticals, Inc.

Nurix Therapeutics, Inc.

Coherus BioSciences, Inc.

Oric Pharmaceuticals, Inc.

Icosavax, Inc.

KalVista Pharmaceuticals, Inc.

Erasca, Inc.

Cullinan Therapeutics, Inc.

Why is Arcutis Biotherapeutics, Inc. ?

With a growth in Net Sales of 164.13%, the company declared Outstanding results in Jun 25

The company has declared positive results for the last 7 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD -65.5 MM
ROCE(HY) Highest at -57.33%
RAW MATERIAL COST(Y) Fallen by -2.32% (YoY)

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating performance in long term as well as near term

Along with generating 185.33% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Arcutis Biotherapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Arcutis Biotherapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Arcutis Biotherapeutics, Inc.

153.95%

4.43

69.40%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

205.12%

EBIT Growth (5y)

1.29%

EBIT to Interest (avg)

-54.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.63

Sales to Capital Employed (avg)

0.41

Tax Ratio

0.47%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.02

EV to EBIT

-13.39

EV to EBITDA

-14.01

EV to Capital Employed

31.00

EV to Sales

7.63

PEG Ratio

Dividend Yield

ROCE (Latest)

-231.44%

ROE (Latest)

-91.38%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -65.5 MM

ROCE(HY)

Highest at -57.33%

RAW MATERIAL COST(Y)

Fallen by -2.32% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.9 times

NET SALES(Q)

Highest at USD 81.5 MM

PRE-TAX PROFIT(Q)

At USD -15.54 MM has Grown at 70.41%

NET PROFIT(Q)

At USD -15.89 MM has Grown at 69.76%

-2What is not working for the Company

CASH AND EQV(HY)

Lowest at USD 389.84 MM

DEBT-EQUITY RATIO (HY)

Highest at -58.26 %

Here's what is working for Arcutis Biotherapeutics, Inc.

Net Sales

At USD 81.5 MM has Grown at 164.13%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Operating Cash Flow

Highest at USD -65.5 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 81.5 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Pre-Tax Profit

At USD -15.54 MM has Grown at 70.41%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -15.89 MM has Grown at 69.76%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Inventory Turnover Ratio

Highest at 1.9 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -2.32% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Arcutis Biotherapeutics, Inc.

Cash and Eqv

Lowest at USD 389.84 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -58.26 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio